a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announces thatThe New England Journal of Medicine(NEJM) has published a peer-reviewed Letter to the Editor describing the PEMGARDA™ (pemivibart) immunobridging emergency use authori...
“People who are immunocompromised continue to be disproportionally impacted by COVID-19 even after receiving multiple vaccine doses,” saidCameron R. Wolfe, M.B.B.S., M.P.H., Professor of Medicine, Transplant Infectious Disease atDuke University School of Medicine. “I’m ex...